Novartis to Build $23B RLT Manufacturing Site in Texas – Expands Radioligand Therapy Production Capacity
Novartis (NYSE: NVS) announced plans to establish a new 46,000‑square‑foot radioligand therapy (RLT) manufacturing site in...
Novartis
Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion
Novartis AG (NYSE: NVS) has entered a long-term supply agreement with Niowave Inc., a US-based isotope...
Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego
Novartis AG (NYSE: NVS) held a groundbreaking ceremony for a state-of-the-art global biomedical research center...
Novartis Revenue Growth Hits 8% Despite Entresto and Promacta Generic Erosion
Novartis AG (NYSE: NVS) reported full‑year 2025 net sales of USD 54.5 billion, up 8% year‑on‑year (YOY) at...
Zonsen Peplib Signs Eli Lilly Deal After Novartis Partnership
Zonsen Peplib Biotech Inc., a China‑based polypeptide lead compound developer, announced a collaboration with Eli...
Novartis Cosentyx Wins NMPA Approval for Non-Radiographic Axial Spondyloarthritis
Novartis (NYSE: NVS) announced that the National Medical Products Administration (NMPA) has approved Cosentyx (secukinumab) for...
Leqvio Gets NMPA Nod for Monotherapy in China Hypercholesterolemia
Novartis (NYSE: NVS) announced that Leqvio (inclisiran) has received an additional indication approval from the National...
China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy
China Isotope & Radiation Corporation (HKG: 1763) announced it has officially entered into a commercial...
Novartis’s Ianalumab Wins FDA Breakthrough Therapy Designation for Sjögren’s Disease
Novartis AG (NYSE: NVS) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...
SciNeuro Pharmaceuticals Licenses Alzheimer’s BBB Antibody Platform to Novartis in $1.5 Billion Deal
SciNeuro Pharmaceuticals announced a global collaboration with Novartis AG (NYSE: NVS) to advance its next‑generation amyloid...
Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity
Novartis AG (NYSE: NVS) announced plans to construct its fourth radiopharmaceutical therapy (RLT) manufacturing facility in...
Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset
Novartis (NYSE: NVS) announced it has secured exclusive global rights to an undisclosed peptide asset...
Novartis MSD Sanofi TrumpRx Deal Targets Medicaid Pricing
Novartis (NYSE: NVS), MSD (NYSE: MRK), and Sanofi (NASDAQ: SNY) announced partnerships with the U.S....
Relation Therapeutics and Novartis Forge $1.7 Billion Alliance for AI‑Driven Atopic Disease Targets
Relation Therapeutics Limited announced a multi‑program strategic collaboration with Novartis AG (NYSE: NVS) to discover...
Novartis’ Remibrutinib Wins NMPA Approval for Chronic Spontaneous Urticaria
Novartis AG (NYSE: NVS) announced that remibrutinib tablets received National Medical Products Administration (NMPA) approval...
Novartis’s Itvisma Wins FDA Approval as First Gene Therapy for SMA
Novartis AG (NYSE: NVS) announced that Itvisma (onasemnogene abeparvovec‑brve) received U.S. FDA approval for children...
Novartis Builds $23B North Carolina Manufacturing Hub, Adding 700 Jobs
Novartis (NYSE: NVS) announced plans to establish a flagship manufacturing hub in North Carolina as...
Novartis Wins FDA Approval for Remibrutinib Tablets – First BTK Inhibitor for Chronic Spontaneous Urticaria
Novartis AG (NYSE: NVS) announced that the U.S. Food and Drug Administration (FDA) has granted...
Pluvicto Radioligand Therapy Receives Dual NMPA Approvals in China
Novartis (NYSE: NVS) has announced that its Lutetium‑177‑labelled therapy Pluvicto (lutetium ¹⁷⁷Lu‑vipivotide tetraxetan) now holds...
Novartis Strikes USD 12b Deal for Avidity’s RNA Therapeutics and Gene-Targeted Pipeline
Novartis (NYSE: NVS) announced an agreement to acquire San Diego-based biotech Avidity Biosciences for USD...